profit from every $100 of sales.
$0$100
Citius Pharmaceuticals
$0.54+0.56% today
-47.0% in 1 year
1-year low $0.371-year high $1.44
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Citius Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$37.4 million of profit last year.
SalesProfit
Citius Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Citius Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Citius Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -33 | -37 | -42 | -39 | |
| -33 | -37 | -42 | -38 | |
| -34 | -33 | -39 | -37 | |
| -5.75 | -5.57 | -5.97 | -3.38 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 114 | 104 | 117 | 131 |
| Cash | 42 | 26 | 3 | 4 |
| Total debt | 1 | 0 | 0 | 2 |
| Total liabilities | 11 | 12 | 43 | 53 |
| 103 | 91 | 70 | 68 | |
| 6 | 6 | 7 | 11 | |
| -25.4% | -31.8% | -47.2% | -43.8% | |
| -32.7% | -35.8% | -55.9% | -55.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -29 | -28 | -27 | |
| – | – | – | – | |
| -28 | -29 | -28 | -27 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 7 | 12 | 11 |
Valuation
- –
- 0.3×
- –
- 0.2×
- –
- –
- –
- -180.8%
- -254.8%
- 0.0%
Profitability
- 61.4%
- -950.9%
- -909.9%
- -930.1%
- -36.3%
- -39.0%
- -52.5%
- -25.6%
- -36.7%
- 218.8%
Growth
- –
- –
- +5.8%
- –
- +11.2%
Financial health
- 0.2×
- 0.02
- 1.3%
- -88.6×
- 0.99
- 0.40
- 0.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 964
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.95 | -0.28 | −238.4% |
| Feb 13, 2026 | -0.38 | 0.43 | −188.4% |
| Dec 25, 2025 | -0.44 | -0.24 | −83.6% |
| Aug 12, 2025 | -0.80 | -0.24 | −233.3% |
| May 14, 2025 | -1.27 | -1.08 | −17.6% |
| Feb 14, 2025 | -1.30 | -1.25 | −4.0% |
| Jan 3, 2025 | -1.75 | -0.04 | −4,275.0% |
| Aug 12, 2024 | -1.50 | -1.25 | −20.0% |
News
Citius Oncology GAAP EPS of -$0.08 beats by $0.11, revenue of $1.5M misses by $4.27MSeeking Alpha · Aug 17, 2026The newest story we have is from Aug 17, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
61Pass
Philip Fisher
50No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
45No pass
Terry Smith
35No pass
Questions about Citius Pharmaceuticals
Is Citius Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Citius Pharmaceuticals AI analysis
What does Citius Pharmaceuticals do?
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. It is in Biotechnology.
Does Citius Pharmaceuticals pay a dividend?
No. Citius Pharmaceuticals does not pay a dividend at the moment.
Is Citius Pharmaceuticals stock halal?
Yes. Citius Pharmaceuticals passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
How has Citius Pharmaceuticals stock done over the past year?
Down 47.0% over the past twelve months, to $0.54. It traded between $0.37 and $1.44 and is 62.8% below its high.
Who are Citius Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Citius Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.